Author: Bari, Elia; Ferrarotti, Ilaria; Saracino, Laura; Perteghella, Sara; Torre, Maria Luisa; Richeldi, Luca; Corsico, Angelo Guido
Title: Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae? Cord-id: 2z44gpm1 Document date: 2021_5_14
ID: 2z44gpm1
Snippet: To date, more than 100 million people worldwide have recovered from COVID-19. Unfortunately, although the virus is eradicated in such patients, fibrotic irreversible interstitial lung disease (pulmonary fibrosis, PF) is clinically evident. Given the vast numbers of individuals affected, it is urgent to design a strategy to prevent a second wave of late mortality associated with COVID-19 PF as a long-term consequence of such a devastating pandemic. Available antifibrotic therapies, namely ninteda
Document: To date, more than 100 million people worldwide have recovered from COVID-19. Unfortunately, although the virus is eradicated in such patients, fibrotic irreversible interstitial lung disease (pulmonary fibrosis, PF) is clinically evident. Given the vast numbers of individuals affected, it is urgent to design a strategy to prevent a second wave of late mortality associated with COVID-19 PF as a long-term consequence of such a devastating pandemic. Available antifibrotic therapies, namely nintedanib and pirfenidone, might have a role in attenuating profibrotic pathways in SARS-CoV-2 infection but are not economically sustainable by national health systems and have critical adverse effects. It is our opinion that the mesenchymal stem cell secretome could offer a new therapeutic approach in treating COVID-19 fibrotic lungs through its anti-inflammatory and antifibrotic factors.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and lung architecture: 1, 2
- acute ards respiratory distress syndrome and lung condition: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acute ards respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute ards respiratory distress syndrome and lung disorder: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute ards respiratory distress syndrome and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67
- acute ards respiratory distress syndrome and lung function decline: 1, 2
- acute ards respiratory distress syndrome and lung regeneration: 1, 2, 3, 4, 5, 6, 7
- acute phase and long term consequence: 1, 2, 3
- acute phase and long term impairment: 1, 2, 3, 4, 5
- acute phase and lung condition: 1
- acute phase and lung diffusion: 1, 2, 3
- acute phase and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
- acute phase and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- acute phase and lung function life: 1, 2
- acute phase infection and long term impairment: 1
- acute phase infection and lung condition: 1
- acute phase infection and lung disease: 1, 2, 3, 4, 5, 6, 7
- acute phase infection and lung function: 1, 2
- acute respiratory syndrome and long term consequence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Co phrase search for related documents, hyperlinks ordered by date